458 related articles for article (PubMed ID: 17200219)
1. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
Arnold DM; Dentali F; Crowther MA; Meyer RM; Cook RJ; Sigouin C; Fraser GA; Lim W; Kelton JG
Ann Intern Med; 2007 Jan; 146(1):25-33. PubMed ID: 17200219
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for children with immune thrombocytopenia: a systematic review.
Liang Y; Zhang L; Gao J; Hu D; Ai Y
PLoS One; 2012; 7(5):e36698. PubMed ID: 22666325
[TBL] [Abstract][Full Text] [Related]
3. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
4. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
Stasi R; Pagano A; Stipa E; Amadori S
Blood; 2001 Aug; 98(4):952-7. PubMed ID: 11493438
[TBL] [Abstract][Full Text] [Related]
5. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
6. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
Gómez-Almaguer D
Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for patients with idiopathic thrombocytopenic purpura.
Peñalver FJ; Cabrera JR
Ann Intern Med; 2007 Aug; 147(4):281; author reply 281-2. PubMed ID: 17709765
[No Abstract] [Full Text] [Related]
11. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura.
Gall B; Yee A; Berry B; Bircham D; Hayashi A; Dansereau J; Hart J
J Obstet Gynaecol Can; 2010 Dec; 32(12):1167-1171. PubMed ID: 21176329
[TBL] [Abstract][Full Text] [Related]
12. Rituximab treatment for symptomatic chronic ITP.
Tamminga RY; Bruin MC
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):714-6. PubMed ID: 16933264
[TBL] [Abstract][Full Text] [Related]
13. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review.
Vesely SK; Perdue JJ; Rizvi MA; Terrell DR; George JN
Ann Intern Med; 2004 Jan; 140(2):112-20. PubMed ID: 14734334
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
15. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P
Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354
[TBL] [Abstract][Full Text] [Related]
16. Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency.
Al-Ahmad M; Al-Rasheed M; Al-Muhani A
J Investig Allergol Clin Immunol; 2010; 20(3):259-62. PubMed ID: 20635793
[TBL] [Abstract][Full Text] [Related]
17. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.
Bennett CM; Rogers ZR; Kinnamon DD; Bussel JB; Mahoney DH; Abshire TC; Sawaf H; Moore TB; Loh ML; Glader BE; McCarthy MC; Mueller BU; Olson TA; Lorenzana AN; Mentzer WC; Buchanan GR; Feldman HA; Neufeld EJ
Blood; 2006 Apr; 107(7):2639-42. PubMed ID: 16352811
[TBL] [Abstract][Full Text] [Related]
18. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.
Giagounidis AA; Anhuf J; Schneider P; Germing U; Söhngen D; Quabeck K; Aul C
Eur J Haematol; 2002 Aug; 69(2):95-100. PubMed ID: 12366712
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
[TBL] [Abstract][Full Text] [Related]
20. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
Zhou Z; Yang R
Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
